---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-23-000083"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T12:13:40.880184+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Instil Bio Q2 2023 net loss $18.7M; cash $202.9M, ITIL-306 trial start 2H 2023

## Summary
- Net loss of $18.7M ($0.14/share) vs. $59.0M loss in Q2 2022; R&D expenses down to $8.5M from $41.5M.
- Cash, equivalents, restricted cash and marketable securities $202.9M as of June 30, 2023; cash runway expected beyond 2026.
- ITIL-306 (CoStAR-TIL) clinical trial ITIL-306-202 anticipated to start in 2H 2023; initial data expected in 2024.
- Manufacturing process improvements doubled CoStAR-TIL yield in final product from verification runs.
- Restructuring and impairment charges of $1.0M in Q2 and $25.6M for six months ended June 30, 2023.

## SEC filing metadata
- accession: 0001789769-23-000083
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976923000083/0001789769-23-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976923000083/til-20230814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-23-000083
- JSON: https://secwatch.observer/filing/0001789769-23-000083.json
- Plain text: https://secwatch.observer/filing/0001789769-23-000083.txt

## Key facts
- Earnings Releases
  Instil Bio, Inc. reported second quarter 2023 results: net income $0.58 for the six months ended June 30, 2023, EPS $0.14 for the three months ended June 30, 2023.
  - Period: second quarter 2023
  - Net income: $0.58 for the six months ended June 30, 2023
  - EPS: $0.14 for the three months ended June 30, 2023
  - Result: reported results
  source text: Instil Bio, Inc. (the "Company") provided a corporate update and announced its financial results for the quarter ended June 30, 2023 in the press release attached hereto as Exhibit 99.1
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789769/000178976923000083/0001789769-23-000083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.